Finally, it is the 21st of July and the long awaited trial “results” from everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) have arrived! Well, not really, because the company didn’t really announce any real results this morning (read more about that here). What The NaDDir* did announce was a collection of bizarre ramblings about wonder drug leronlimab‘s supposed safety from the Phase 2 trial of leronlimab in mild/moderate Covid patients (trial details here).
From this morning’s press release:
The headline? Impressive Results….39% of patients in (the) placebo arm had SAEs as compared to only 14% of patients in (the) leronlimab arm.
More like impressive bullshit. Just a few lines later one can see that 6 out of 28 patients in the placebo arm, and 5 out of 56 patients in the leronlimab arm reported SAEs. That’s actually 21.4% and 8.9%.
Coming from the same klown krew who still can’t manage to file an acceptable BLA submission, is their failure to do simple math much of a surprise? Or was this a deliberate deception to make leronlimab somehow look more appealing in front of tomorrow’s shareholder meeting where management is hoping to get another 100mm shares authorized so the dilution can continue unimpeded.
*Spelled thusly for a double dose of that sweet sweet stock pimping.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.